Insider Buying: Neonc Technologies (NASDAQ:NTHI) CEO Acquires $20,001.60 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Thomas Chen acquired 5,556 shares of the business’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $3.60 per share, with a total value of $20,001.60. Following the acquisition, the chief executive officer owned 19,261 shares in the company, valued at $69,339.60. The trade was a 40.54% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Neonc Technologies Price Performance

Shares of NTHI stock traded down $0.47 during trading hours on Tuesday, reaching $3.31. The company had a trading volume of 285,988 shares, compared to its average volume of 104,731. Neonc Technologies Holdings, Inc. has a 12-month low of $3.01 and a 12-month high of $12.99. The stock has a fifty day moving average of $4.04 and a 200-day moving average of $5.27.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Institutional Investors Weigh In On Neonc Technologies

Several large investors have recently bought and sold shares of the stock. Global Retirement Partners LLC purchased a new position in shares of Neonc Technologies in the 2nd quarter valued at about $126,000. BlackRock Inc. purchased a new stake in shares of Neonc Technologies during the second quarter worth approximately $815,000. Westmount Partners LLC raised its holdings in Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in Neonc Technologies in the second quarter valued at approximately $1,017,000.

Key Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Analysts Set New Price Targets

NTHI has been the topic of a number of analyst reports. Maxim Group assumed coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings raised shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Alliance Global Partners initiated coverage on shares of Neonc Technologies in a report on Tuesday, May 19th. They set a “buy” rating and a $13.00 price target for the company. Wall Street Zen cut shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.